company background image
AUPH logo

Aurinia Pharmaceuticals NasdaqGM:AUPH Stock Report

Last Price

US$5.95

Market Cap

US$860.5m

7D

1.7%

1Y

-27.4%

Updated

24 Feb, 2024

Data

Company Financials +

Aurinia Pharmaceuticals Inc.

NasdaqGM:AUPH Stock Report

Market Cap: US$860.5m

AUPH Stock Overview

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States.

AUPH fundamental analysis
Snowflake Score
Valuation5/6
Future Growth4/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Aurinia Pharmaceuticals Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Aurinia Pharmaceuticals
Historical stock prices
Current Share PriceUS$5.95
52 Week HighUS$12.43
52 Week LowUS$5.35
Beta1.46
1 Month Change-26.00%
3 Month Change-35.11%
1 Year Change-27.35%
3 Year Change-57.50%
5 Year Change-12.37%
Change since IPO190.24%

Recent News & Updates

Analysts Have Been Trimming Their Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Price Target After Its Latest Report

Feb 19
Analysts Have Been Trimming Their Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Price Target After Its Latest Report

Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) 26% Dip In Price Shows Sentiment Is Matching Revenues

Feb 17
Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) 26% Dip In Price Shows Sentiment Is Matching Revenues

Aurinia Pharmaceuticals 2023 Earnings Review: Calling 'Time' In Last Chance Saloon

Feb 15

Recent updates

Analysts Have Been Trimming Their Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Price Target After Its Latest Report

Feb 19
Analysts Have Been Trimming Their Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Price Target After Its Latest Report

Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) 26% Dip In Price Shows Sentiment Is Matching Revenues

Feb 17
Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) 26% Dip In Price Shows Sentiment Is Matching Revenues

Aurinia Pharmaceuticals 2023 Earnings Review: Calling 'Time' In Last Chance Saloon

Feb 15

Aurinia Pharmaceuticals: Sales Growth Would Help Buyout Potential

Jan 28

We're Interested To See How Aurinia Pharmaceuticals (NASDAQ:AUPH) Uses Its Cash Hoard To Grow

Jan 05
We're Interested To See How Aurinia Pharmaceuticals (NASDAQ:AUPH) Uses Its Cash Hoard To Grow

Insufficient Growth At Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Hampers Share Price

Dec 18
Insufficient Growth At Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Hampers Share Price

Aurinia Pharmaceuticals (NASDAQ:AUPH) Is In A Strong Position To Grow Its Business

Sep 14
Aurinia Pharmaceuticals (NASDAQ:AUPH) Is In A Strong Position To Grow Its Business

Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) Low P/S No Reason For Excitement

Jun 11
Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) Low P/S No Reason For Excitement

Broker Revenue Forecasts For Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Are Surging Higher

May 09
Broker Revenue Forecasts For Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Are Surging Higher

We're Not Worried About Aurinia Pharmaceuticals' (NASDAQ:AUPH) Cash Burn

May 01
We're Not Worried About Aurinia Pharmaceuticals' (NASDAQ:AUPH) Cash Burn

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Analysts Just Trimmed Their Revenue Forecasts By 26%

Nov 04
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Analysts Just Trimmed Their Revenue Forecasts By 26%

Aurinia Pharmaceuticals wins European approval of Lupkynis for lupus

Sep 19

Aurinia Pharmaceuticals: The Right Play Now

Aug 24

Aurinia Pharmaceuticals: Updating My Revenue And Valuation Model

Aug 15

Aurinia Pharma Q2 2022 Earnings Preview

Aug 03

Aurinia lupus nephritis drug recommended in Europe

Jul 22

A Buyout-Driven Pair Trade: Buy Aurinia, Sell Merck (Or Seagen If You Must)

Jul 04

Aurinia: Redemption On Lupkynis Sales And Possible EMA Approval

May 20

Analysts Just Slashed Their Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) EPS Numbers

Mar 10
Analysts Just Slashed Their Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) EPS Numbers

Shareholder Returns

AUPHUS BiotechsUS Market
7D1.7%1.5%1.3%
1Y-27.4%10.5%25.6%

Return vs Industry: AUPH underperformed the US Biotechs industry which returned 8.1% over the past year.

Return vs Market: AUPH underperformed the US Market which returned 23.3% over the past year.

Price Volatility

Is AUPH's price volatile compared to industry and market?
AUPH volatility
AUPH Average Weekly Movement10.0%
Biotechs Industry Average Movement11.4%
Market Average Movement6.1%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.1%

Stable Share Price: AUPH's share price has been volatile over the past 3 months.

Volatility Over Time: AUPH's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1993300Peter Greenleafhttps://www.auriniapharma.com

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd.

Aurinia Pharmaceuticals Inc. Fundamentals Summary

How do Aurinia Pharmaceuticals's earnings and revenue compare to its market cap?
AUPH fundamental statistics
Market capUS$860.48m
Earnings (TTM)-US$78.02m
Revenue (TTM)US$175.51m

4.9x

P/S Ratio

-11.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AUPH income statement (TTM)
RevenueUS$175.51m
Cost of RevenueUS$21.68m
Gross ProfitUS$153.83m
Other ExpensesUS$231.85m
Earnings-US$78.02m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.54
Gross Margin87.65%
Net Profit Margin-44.45%
Debt/Equity Ratio0%

How did AUPH perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.